Contents

Search


foscarnet (Foscavir)

Tradename: Foscavir. A virustatic agent. Indications: - CMV retinitis: 1) indications a patients with ganciclovir-resistant CMV b) patients who cannot tolerate ganciclovir 2) induction therapy -> 60 mg/kg every 8 hours or 90 mg/kg every 12 hours IV for 2-3 weeks 3) maintenance therapy: 90-120 mg/kg/day 4) foscarnet is administered IV as a 1-2 hour infusion 5) daily infusions of normal saline (1 liter) may reduce nephrotoxicity - Varicella zoster [5] - Herpes simplex Dosage: Injection: 24 mg/mL (250 mL, 500 mL) Dosage adjustment in renal failure: (maintenance) - 25 mg/kg every 8 hours GFR > 50 mL/min - 15 mg/kg every 8 hours GFR 10-50 mL/min - 6 mg/kg every 8 hours GFR < 10 mL/min Pharmacokinetics: 1) elimination 1/2life 3 hours 2) terminal 1/2life of 18-88 hours Adverse effects: 1) common (> 10%) - fever, nausea, anemia, diarrhea, renal insufficiency, headache, seizures 2) less common (1-10%) - fevers, rigors, asthenia, malaise, pain at site of injection, sepsis, paresthesias, dizziness, involuntary muscle contractions, hypoesthesia, neuropathy, anorexia, granulocytopenia, leukopenia, electrolyte disorder, depression, confusion, anxiety, coughing, dyspnea, rash, increased sweating, visual disturbance 3) uncommon (< 1%) - hypothermia, peripheral edema, ascites, syncope, substernal chest pain, abnormal crying, malignant hyperpyrexia, heart failure, bradycardia, arrhythmias, vertigo, coma, abnormal gait, hypertonia, dyskinesia, vocal cord paralysis, speech disorder, cerebral edema, nystagmus, gynecomastia 4) other [4] - hypocalcemia (decreased ionized calcium) - hypomagnesemia - hypophosphatemia Test interactions: - decreased serum gonadotropins Mechanism of action: 1) pyrophosphate that inhibits Herpesvirus DNA polymerase 2) does NOT require intracellular phosphorylation for activity 3) active against viruses deficient in thymidine kinase

Interactions

drug interactions

General

antiviral agent pyrophosphate

Properties

MISC-INFO: elimination route KIDNEY pregnancy-category C safety in lactation ?

Database Correlations

PUBCHEM correlations

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Manual of Medical Therapeutics, 28th ed, Ewald & McKenzie (eds), Little, Brown & Co, Boston, 1995, pg 294
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  4. Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
  5. Deprecated Reference
  6. Department of Veterans Affairs, VA National Formulary